bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version about us  about us gradient is developing a novel transvascular catheter based technology based on proven clinical human data to treat pulmonary hypertension a fatal condition that effects approximately  patients per year worldwide this disruptive therapy results in a reduction in pulmonary vascular resistance and improvement in cardiovascular hemodynamics symptoms and costs of care and has shown breakthrough potential as a lifesaving treatment search archives meta log in gradient pharmaceuticals inc private company information  bloomberg july    pm et biotechnology company overview of gradient pharmaceuticals inc snapshot people company overview gradient pharmaceuticals inc operates in the healthcare industry focusing on biotechnology business the company was incorporated in  and is based in houston texas  holcombe boulevardtmcx suite houston tx united statesfounded in  phone  key executives for gradient pharmaceuticals inc mr valentin angelkov chief executive officer and director mr martin martinov executive director compensation as of fiscal year  similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target private placement october    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact gradient pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close contracting profile gradient pharmaceuticals inc houston tx   gradient pharmaceuticals inc  houston tx vendor  vendors gradient pharmaceuticals inc  houston tx add alert sign up actions add to partners claim vendor similar vendors related contracts related projects help gradient pharmaceuticals inc houston tx federal vendor last active  weeks ago  of  with  ratings welcome to govtribe we provide leading federal market intel and awesome tools to manage your pursuit process plans start at  a month try for free welcome to govtribe we help you find federal opportunities scout the competition and manage your pursuit process plans start at  a month try for free name gradient pharmaceuticals inc houston tx division not listed parent not listed address  holcombe blvd ste tmcx  houston tx  usa website not listed primary category not listed size not listed contacts valentin angelkov salesebusiness p  structure corporate entity not tax exempt designations grants gradient pharmaceuticals inc ceo and executives  bloomberg july    pm et biotechnology company overview of gradient pharmaceuticals inc snapshotpeople  overviewboard memberscommittees key executives for gradient pharmaceuticals inc nameboard relationshipstitleagevalentin angelkov  relationshipschief executive officer and directormartin martinov  relationshipsexecutive director gradient pharmaceuticals inc board members nameboard relationshipsprimary companyagevalentin angelkov  relationshipsgradient pharmaceuticals incmartin martinov  relationshipsgradient pharmaceuticals incmax duckworth  relationshipsmasa impact llcview all board members gradient pharmaceuticals inc executive committees committee namechairpersonboard relationshipsmembersthere is no committee data available data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup ceo compensation in this industry  industry rangesalary kbonus ktotal short term compensation ktotal value of options mcompensation as of fiscal year gradient pharmaceuticals inc ceo compensationindustry average industry executive changesmoleculin biotech inc announces resignation of jacqueline northcut as company’s board of directorsjuly    pm etbiocon limited announces the resignation of john mccallum marshall shaw as whole time directorjuly    pm etc therapeutics announces appointments to its scientific advisory boardjuly    pm etaduro biotech inc announces executive changesjuly    pm etintec pharma ltd promotes nadav navon to chief operating officerjuly    pm etsponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact gradient pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft gradient  pharmaceuticals biopharmaceuticals about gradient services  projects people evolving issues news  events publications careers contact us about gradient celebrating  years now locations where we have worked chemicals we have worked on community involvement partnerships for the common good services  projects product stewardship and safety pharmaceuticals medical devices predictive toxicology biocompatibility nanotechnology endocrine disrupting chemicals dietary supplements food safety consumer products green chemistry risk sciences toxicology  risk sciences exposure  risk assessment epidemiology ecological risk toxic torts occupational health  safety geneenvironment interactions coal combustion products pesticides radiation methods  policy perfluorinated compounds environmental sciences chemistryforensics chemical fate  transport data quality management remedial strategies hydraulic fracturing air quality geographic information system climate impacts water resources environmental cost analysis insurance claims prp cost recoveryallocation environmental cost estimation global regulatory compliance chemical registration scientific comment ghs hazard assessment safety data sheets tsca prop  peopleprincipals barbara d beckleslie a beyerandrew b bittnerteresa s bowerscatherine petito boyceeric l butlersamuel a flewellingjulie e goodmankurt hermandavid e langsethtom a lewandowskiari s lewischristopher m longdavid e merrillkim reynolds reidlorenz r rhombergmanu sharmapeter a valbergtim verslyckea dallas wait senior scientists lisa a baileyali boroumandnicole l briggsjoel m cohentravis j cookdavid g dodgeeric m dubegrace i greenbergmary l hixonlaura e kerperjessie m kneelandcynthia j langloisjulie c lemaylaurent c levytamara d lunsmanheather n lynchrosemary mattuckdavid b mayfieldmatthew j mayoisaac moharmichael k petersondaniella m pizzurromargaret c pollockrobyn l prueittkathleen a radloffjames w ricejeffrey t romingermara seeleydaniel skallmeghna h swamycaroline b tuitmatthew p tymchakjiaru zhangkirsten ke zu research  information specialists evolving issues news  events recent scientific papers careers working at gradient current openings continuous recruiting benefits directions services overview product stewardship and safetypharmaceuticals medical devices predictive toxicology biocompatibility nanotechnology endocrine disrupting chemicals dietary supplements food safety consumer products green chemistry risk sciences environmental sciences environmental cost analysis global regulatory compliance product stewardship and safety pharmaceuticals biopharmaceuticals overview example projects experts overview gradient assists the pharmaceutical industry with our broad experience related to the environmental and mammalian toxicology of pharmaceutical compounds staff toxicologists offer comprehensive support throughout the drug development process  at the target identification stage our toxicology team offers technical and strategic solutions for preclinical toxicological safety assessment  inhouse expertise in alternative testing strategies including readacross and various in silico tools derek nexustm leadscope oecd qsar toolbox toxtree facilitates comparative toxicity screens for hazard and risk assessment of unusual and proprietary chemicals  as a third party consultant licensee gradient offers in silico statistical and expertrulebased evaluation of impurities to meet ich m requirements  gradient scientists assist in the design monitoring and interpretation on nonclinical toxicology toxicokinetic and pharmacokinetic studies in addition to the preparation of various regulatory and marketing submissions including investigational new drug ind new drug application nda biologics license application bla clinical trial applications cta and marketing authorization application maa submissions  our environmental scientists have extensive expertise in the evaluation of pharmaceuticals in the environment new regulatory requirements environmental safety testing and assessment to support regulatory submissions   example projects drug registration environmental assessments full description gradient conducted several regulatory environmental assessments compliant with fda and ema requirements for a wide range of active pharmaceutical ingredients from relatively low toxicity to endocrineactive compounds we designed and oversaw required environmental fate and toxicity testing and prepared the environmental assessment reports deriving predicted no effect concentrations for pharmaceutical ingredients full description as an integral component of new drug regulatory approval gradient developed an approach for developing predicted no effect concentrations pnecs for pharmaceutical ingredients with limited available environmental data we reviewed an extensive dataset of active pharmaceutical ingredients apis and developed a streamlined environmentally protective approach for estimating pnecs for apis when little environmental toxicity data are available critique of proposed eu pharmaceutical environmental assessment requirements full description gradient provided comments on the euproposed pharmaceutical environmental assessment requirements we recommended a streamlined scientifically sound tiered fateandeffects data collection and assessment program toxicological evaluation of alexidine treated catheters full description gradient evaluated the potential clinical exposure and toxicological hazard associated with the use of the antimicrobial agent alexidine and its degradation products when incorporated into a peripherally inserted central catheter we utilized biocompatibility test results and prepared a toxicological profiles for alexidine and its degradation products using in silico toxicity prediction tools to determine the margin of safety based on the results we concluded that there was a low potential hazard associated with clinical use of alexidine coated catheters at the levels examined our report was submitted to fda immunology of novel skin cancer treatments full description for a biotech company gradient evaluated flow cytometry data to gauge human immune responses to skin cancer treatments we aided in the development of new assays to better understand dermal tumor immunology our advice advanced the clients research and development of skin cancer treatments pre and postind toxicity study design and oversight full description for a small molecule initially provided preind toxicology study support as the scientific lead for the conduct of outsourced studies including safety pharmacology  genetic toxicology  and repeatdose toxicology following ind approval we monitored day studies performed in rodents and primates maintained direct oversight over the study conduct data analysis interpretation and reporting experts joel m cohen read biojulie e goodman read biotom a lewandowski read biotamara d lunsman read bioisaac mohar read biodaniella m pizzurro read biolorenz r rhomberg read biomanu sharma read biotim verslycke read bio the environmental presence of chemicals designed to be biologically active raises concern for potential impacts on wildlife tim verslycke gradient principal scientist from are pharmaceuticals posing a risk to the environment read the article in trends related servicespredictive toxicology nanotechnology image courtesy of usgsnasa landsat main office  gradient is a service mark and the gradient logo is a registered service mark of gradco llc gradient  pharmaceuticals about gradient services  projects people evolving issues news  events publications careers contact us about gradient celebrating  years locations where we have worked chemicals we have worked on community involvement services  projects product stewardship and safety endocrine disrupting chemicals nanotechnology medical devices biocompatibility dietary supplements consumer products green chemistry risk sciences toxicology  risk sciences exposure  risk assessment epidemiology ecological risk toxic torts occupational health  safety geneenvironment interactions coal combustion products pesticides radiation perfluorinated compounds environmental sciences chemistryforensics chemical fate  transport data quality management remedial strategies hydraulic fracturing air quality geographic information system water resources environmental cost analysis insurance claims prp cost recoveryallocation environmental cost estimation regulatory compliance reach chemical registration scientific comment pharmaceuticals food safety methods  policy peopleprincipals barbara d beckleslie a beyerandrew b bittnerteresa s bowerscatherine petito boyceeric l butlersamuel a flewellingjulie e goodmankurt hermandavid e langsethtom a lewandowskiari s lewischristopher m longdavid e merrillkim reynolds reidlorenz r rhombergmanu sharmapeter a valbergtim verslyckea dallas wait senior scientists lisa a baileynicole l briggsjoel m cohentravis j cookdavid g dodgeeric m dubegrace i greenbergmary l hixonlaura e kerperjessie m kneelandcynthia j langloisjulie c lemaylaurent c levytamara d lunsmanheather n lynchrosemary l mattuckdavid b mayfieldmatthew j mayomichael k petersondaniella m pizzurromargaret c pollockrobyn l prueittkathleen a radloffjeffrey t romingermara r seeleymeghna h swamycaroline b tuitmatthew p tymchakjiaru zhangkirsten ke zu research  information specialists evolving issues news  events recent scientific papers careers working at gradient continuous recruiting benefits directions services overview product stewardship and safety risk sciences environmental sciences environmental cost analysis regulatory compliancereach chemical registration scientific comment pharmaceuticals food safety methods  policy regulatory compliance pharmaceuticals overview example projects experts overview gradient assists the pharmaceutical industry with our broad experience related to the environmental and mammalian toxicology of pharmaceutical compounds our environmental scientists have extensive expertise in the evaluation of pharmaceuticals in the environment new regulatory requirements environmental safety testing and assessment to support regulatory submissions in addition we provide pharmaceutical and illicit drug forensic services such as evaluating the potential role of exogenous compounds in causing death disease or disability   example projects drug registration environmental assessments full description gradient conducted several regulatory environmental assessments compliant with fda and ema requirements for a wide range of active pharmaceutical ingredients from relatively low toxicity to endocrineactive compounds we designed and oversaw required environmental fate and toxicity testing and prepared the environmental assessment reports deriving predicted no effect concentrations for pharmaceutical ingredients full description as an integral component of new drug regulatory approval gradient developed an approach for developing predicted no effect concentrations pnecs for pharmaceutical ingredients with limited available environmental data we reviewed an extensive dataset of active pharmaceutical ingredients apis and developed a streamlined environmentally protective approach for estimating pnecs for apis when little environmental toxicity data are available critique of proposed eu pharmaceutical environmental assessment requirements full description gradient provided comments on the euproposed pharmaceutical environmental assessment requirements we recommended a streamlined scientifically sound tiered fateandeffects data collection and assessment program experts tom a lewandowski read biomanu sharma read biotim verslycke read bio the environmental presence of chemicals designed to be biologically active raises concern for potential impacts on wildlife tim verslycke gradient principal scientist from are pharmaceuticals posing a risk to the environment read the article in trends image courtesy of usgsnasa landsat main office  gradient is a service mark and the gradient logo is a registered service mark of gradco llc